SeeMetrics Launches Customizable Cybersecurity Performance Boards, Allowing CISOs To Tailor Their Security Narrative
The newly launched customizable Cybersecurity Performance Boards empower security leaders to manage their own metrics…
Year: 2023
Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
MANNHEIM, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the…
Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
MANNHEIM, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) — Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the…
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical…
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical…
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting
– Four abstracts highlight Gene Circuit platforms that enhance the scope, precision, effectiveness, and controllability…
Senti Bio Announces Multiple Data Presentations at the Society for Immunotherapy of Cancer 2023 Meeting
– Four abstracts highlight Gene Circuit platforms that enhance the scope, precision, effectiveness, and controllability…
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting
ZUG, Switzerland and BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq:…
Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq:…
Cytek® Biosciences Achieves ISO 13485 Certification at Headquarters
Certification Validates Company’s Commitment to Quality in all Areas, Helping to Advance Roadmap for Translational…
Cytek® Biosciences Achieves ISO 13485 Certification at Headquarters
Certification Validates Company’s Commitment to Quality in all Areas, Helping to Advance Roadmap for Translational…
T-knife Therapeutics Announces Four Presentations at the Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN FRANCISCO and BERLIN, Sept. 27, 2023 (GLOBE NEWSWIRE) — T-knife Therapeutics, Inc., a clinical-stage…
T-knife Therapeutics Announces Four Presentations at the Upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN FRANCISCO and BERLIN, Sept. 27, 2023 (GLOBE NEWSWIRE) — T-knife Therapeutics, Inc., a clinical-stage…
Scilex Holding Company Submits a Request to the Securities and Exchange Commission to Withdraw its Registration Statement on Form S-1 (File No. 333-271401)
PALO ALTO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
Scilex Holding Company Submits a Request to the Securities and Exchange Commission to Withdraw its Registration Statement on Form S-1 (File No. 333-271401)
PALO ALTO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex”…
GTG Signs Precision Medicine Pilot with Australia’s Largest Private Hospital Network
GeneType and Gold Coast Hospital Simon Morriss – Genetic Technologies Ltd CEO and Michelle Ferrari…
GTG Signs Precision Medicine Pilot with Australia’s Largest Private Hospital Network
GeneType and Gold Coast Hospital Simon Morriss – Genetic Technologies Ltd CEO and Michelle Ferrari…
Beyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting
Abstract titles to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting…